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ABSTRACT
Introduction: Suspicious adnexal masses need to be investigated thoroughly as it may represent ovarian cancer, which 
is the fourth most common gynaecological cancer in Malaysia. Conventional cross sectional imaging may reveal 
non-specific findings, thus lead to unnecessary biopsies. 18F-Fluorodeoxyglucose positron emission tomography/ 
computed tomography (18F-FDG PET/CT) has emerged as a useful tool, for characterization of indeterminate 
adnexal masses. Most studies have been conducted in Western population, and little information is available in Asian 
population in general and Malaysian population in particular. Methods: Prospective study of women with suspicious 
adnexal masses, referred to the Centre for Nuclear Diagnostic Imaging, Universiti Putra Malaysia to undergo pre-
operative whole-body contrast-enhanced 18F-FDG PET/CT scans from January 2014 to January 2016. Subjects 
underwent Contrast-Enhanced Computed Tomography (CECT) scans followed by positron emission tomography 
(PET) scans using a hybrid scanner. Two radiologists analyzed the CECT and PET/CT images by consensus; blinded to 
the HPE results. Then the PET/CT findings were correlated with HPE results as the gold standard. Results: 11 whole-
body PET/CT scans and 18 adnexal masses (12 HPE-proven malignant lesions and 6 benign lesions) were analyzed. 
The sensitivity, specificity, PPV, and NPV of CECT alone compared to PET/CT was 91.7%, 50.0%, 78.6%, and 75.0% 
vs. 91.7%, 100%, 100% and 85.7% respectively. Conclusions: Improved diagnostic accuracy for characterizing 
benign and malignant adnexal masses can be achieved using contrast-enhanced 18F-FDG PET/CT, making it a 
potential investigation of choice which can help in treatment planning.
Keywords: Postiron emision tomography, Ovarian carcinoma, Adnexal malignancy





Suspicious adnexal masses poses a potential risk of 
being diagnosed as ovarian cancers. It is important to 
thoroughly investigate these masses and to detect ovarian 
cancer as it is the fourth most common gynaecological 
cancer in Malaysia and is usually detected at an 
advanced stage. (1) There are Type I or indolent type of 
ovarian cancers and Type II aggressive type of ovarian 
cancers. Type I cancers include low grade serous, low 
grade endometrioid and mucinous tumors, whereas 
Type II cancers include high grade serous, high grade 
endometrioid, undifferentiated and carcinosarcomas. 
There is experimental evidence that Type II cancers 
may originate from fimbrial ends of Fallopian tubes as 
premalignant serous tubal intraepithelial cancer (STIC) 
lesions and are only detected by conventional imaging 
when it reaches an advanced stage.(2)  
Diagnosis of ovarian cancer is usually made by 
ultrasound, followed by cross sectional imaging such 
as computed tomography (CT) scan (3) or magnetic 
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resonance imaging (MRI) for further characterization 
and staging (4) and confirmed with histopathological 
examination (HPE). Screening by transvaginal ultrasound, 
however, may incidentally detect lesions and lead to 
unnecessary biopsies.(2) Although surgical staging is the 
accepted standard of practice, cross sectional imaging 
such as CT and MRI are essential to guide surgery and 
decide the intervention pathway.(5) It has been noted 
that computed tomography alone is not reliable to 
predict optimal or suboptimal cytoreduction in primary 
debulking surgery.(6)  Hence in the era of molecular 
imaging, 18F-Fluorodeoxyglucose positron emission 
tomography/ computed tomography (18F-FDG PET/
CT) has emerged as a useful tool, for characterization 
of suspicious adnexal masses and staging of ovarian 
carcinomas.(7) 18F-FDG PET/CT is able to quantify 
glucose metabolism by cancer cells in vivo, thus helps 
to non-invasively detect and stage malignant tumors.(8) 
Most studies have been conducted in Western 
population, and little information is available in Asian 
population in general, and Malaysian population in 
particular. Our aim was to assess the current diagnostic 
accuracy of contrast-enhanced PET/CT hybrid imaging 
in characterization of suspicious adnexal masses to 
differentiate between benign and malignant lesions, 
using histopathological results as a gold standard of 
reference, in a Malaysian population. 
MATERIAL AND METHODS
We conducted a prospective study and recruited all 
women with suspicious adnexal masses who were 
referred to the Centre for Diagnostic Nuclear Imaging, 
Universiti Putra Malaysia to undergo pre-operative 
whole-body contrast-enhanced 18F-FDG PET/CT scan 
between the periods of January 2014 to January 2016. 
Subjects were referred from Serdang Hospital, a national 
tertiary referral centre for gynaecological malignancies. 
After receiving ethical clearance from our institutional 
ethical board and national ethical committee (NMRR-
13-852-15672 and NMRR-14-1910-19208 IIR), we 
recruited subjects with suspicious adnexal masses 
based on ultrasound or conventional CT scan imaging. 
Inclusion criteria included women aged 18 years and 
above, having normal serum creatinine level and with 
suspicious adnexal masses and planned for surgery/ 
biopsy within 4 weeks after the PET/CT scan. Exclusion 
criteria were patients with uncontrolled blood sugar 
levels and those who did not undergo biopsy / surgery. 
At our institution, a 64-slice hybrid PET/CT scanner 
with 3D lutetium oxyorthosilicate (LSO) crystals 
(Biograph, SIEMENS, Munich, Germany) was used to 
scan the subjects. The examinations included contrast-
enhanced computed tomography (CECT) scans using 
low osmolar iodinated contrast media, and positron 
emission tomography scan (PET) scans.  Patients were 
instructed to fast for a minimum of 6 hours before 
scanning, and blood glucose level was required to be < 7 
mmol/L before the injection of 18F-fluorodeoxyglucose 
(18F-FDG). 18F-FDG was administered within the dose 
range of 6.72 – 8.26mCi, according to patients’ body 
weight. The CECT is used for anatomic localization of 
FDG, attenuation correction and diagnostic purposes. 
Co-registered contrast-enhanced PET/CT images were 
displayed on the Siemens Leonardo workstation. The 
fused PET/CT images were used for visual interpretation, 
tumor volume and maximum standard uptake value 
(SUVmax) measurements. Two radiologists analysed the 
CECT and PET/CT images separately and by consensus; 
blinded to the histopathological results. Then our 
reviewers correlated these findings with HPE results as 
the gold standard. 
The adnexal masses were visually assessed for signs of 
malignancy such as mixed or solid consistency, presence 
of internal septations and avid enhancement on CECT 
scans. Apart from the adnexal regions, nine other regions 
were evaluated to detect nodal spread and distant 
metastases i.e. pelvic lymph nodes, abdominal lymph 
nodes, uterine, urinary bladder, peritoneum, omentum, 
liver, lungs and bone involvement.
General demographic data of the patient characteristics 
were described using tables for categorical data, and 
medians and range for continuous variables. We used 
SPSS V22.0 for our statistical analysis. Comparison of 
continuous variables was done by chi square test and 
Pearson correlation. A p value of <0.05 was considered 
statistically significant. We also calculated the sensitivity, 
specificity, positive predictive value and negative 
predictive value for both the diagnostic tests of CECT 
and PET/CT compared with the gold standard using 
histopathological results. 
RESULTS 
We scanned 16 women who fulfilled our study criteria, 
but only utilized 11 contrast-enhanced PET/CT scans 
in the final analysis; because 3 women defaulted our 
follow up, one was deceased before surgery could be 
performed, and another had a tumor which was later 
histopathologically confirmed as a huge leiomyoma 
arising from the uterus and not originating from the 
adnexal region. Among the 11 women, 7 of them were 
found to have bilateral ovarian pathology.
Women with malignant adnexal lesions were aged 18 
– 59 years old (mean 43.2 years old, SD 13.07). The 
18-year old woman had a dysgerminoma. The rest of 
the malignant adnexal lesions were epithelial ovarian 
carcinomas (EOC) comprising of various subtypes. 
Women with EOC were older (mean age 46.4 years old, 
SD 9.65); whereas women with benign adnexal lesions 
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were younger aged 19 – 59 years old (mean 38.6 years 
old, SD 16.07). 
There were altogether 18 lesions analysed; 12 were 
malignant adnexal lesions and 6 were benign adnexal 
lesions. The commonest malignant lesions detected were 
high grade serous carcinomas of the ovaries (HGSC) (n=, 
4), followed by mucinous carcinomas of the ovaries (n=2), 
metastatic ovarian tumors originating from carcinoma 
of the colon (n=2), one mixed endometrioid and clear 
cell carcinoma of the ovaries; one dysgerminoma; one 
pure endometrioid carcinoma and one primary ovarian 
pseudomyxoma peritoneii. The benign adnexal lesions 
included corpus luteal cysts (n=2), and one case each 
of fibroma, mature cystic teratoma, adenomyosis and 
mucinous cystadenoma. The range of SUVmax values for 
malignant lesions were 1.68– 18.77 g/mL (mean 7.07, 
SD 4.94) and the SUVmax for benign lesions were 1.07 – 
2.90 g/mL (mean 1.17, SD 0.76). 
DISCUSSION 
From our study, there was no statistically significant 
association between SUVmax values with malignant HPE 
(p=0.11). This was because although generally malignant 
adnexal lesions tended to have higher SUVmax values, 
there was some overlap of values between malignant 
and benign adnexal lesions. In particular, two cases 
of mucinous adenocarcinomas did not demonstrate 
significantly increased FDG hypermetabolism, and their 
SUVmax values were 1.68 g/mL (Figure 1a) and 4.20 g/
mL respectively. Our findings concurred with the known 
caveat for mucinous carcinoma of the ovary which 
often demonstrates only mild to near baseline FDG 
uptake intensity; and can be misinterpreted as a benign 
adnexal lesion, hence giving a falsely negative finding.
(9) Nevertheless, lesions with high SUVmax values i.e. 
demonstrated FDG hypermetabolism, were more likely 
to be malignant, especially lesions of the serous type 
(Figure 1b). 
Positron emission tomography/ computed tomography 
(PET/CT) correctly diagnosed all of the benign adnexal 
lesions and did not give any falsely positive findings. 
However, CECT alone had three cases that gave falsely 
positive findings; which were a fibroma, a mucinous 
adenoma and an adenomyosis. Adenomyosis is a 
known mimicker of malignancy often giving a falsely 
positive CECT findings;(3) however, this lesion only 
demonstrated mild FDG uptake, having SUVmax of 2.9 
g/mL. Fibromas being predominantly solid lesions, are 
also easily misdiagnosed as malignant. Nevertheless 
the fibroma detected in our study had low SUVmax value 
of 2.37 g/mL (Figure 2a) and was correctly interpreted 
as benign. We also detected a case of mucinous 
Fig. 1. FDG uptake in malignant adnexal masses. (a): Mucinous adenocarcinomas of the ovary usually do not demon-
strate significantly increased FDG hypermetabolism, as evidenced by this tumour with SUVmax value of 1.68 g/mL. 
(b): Serous adenocarcinomas of the ovary typically show FDG hypermetabolism, as evidenced by this malignant 
tumour that demonstrated markedly elevated FDG uptake levels (SUVmax 8.50 g/mL) above baseline uptake. 
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Fig. 2. FDG uptake in benign adnexal masses. (a): Axial view contrast-enhanced PET/CT detection of a solid enhancing 
lesion (white arrow) was detected on CT which was considered suspicious for malignancy, but due to its non FDG-
avidity on PET/CT (SUVmax 2.4g/mL), it was deemed benign based on PET criteria and was later confirmed to be a 
benign ovarian fibroma. (b): Axial view contrast-enhanced PET/CT detection of a non FDG-avid right adnexal lesion 
(white arrow), which was predominantly cystic and had fat component and presence of wall calcification (black 
arrow). HPE confirmed it to be a mature cystic teratoma, in keeping with a true negative finding. The contralateral 
ovarian mass was confirmed to be mucinous adenocarcinoma. 
Fig. 3. True negative findings in 18F-FDG PET/CT imaging of suspicious adnexal masses.  (a): Maximum intensity 
projection image of PET demonstrated a non FDG avid large pelvic adnexal tumour causing moderate hydronephro-
sis. (b): Subsequently, axial view fused PET/CT image of the same patient demonstrated a well-defined non FDG-avid 
tumour (white arrow), which appeared benign on PET/CT which was later confirmed by HPE to be a benign muci-
nous cystadenoma.
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adenocarcinoma of the ovary and a case of mature cystic 
teratoma (Figure 2b), both of which did not demonstrate 
increased FDG uptake. Contrast-enhanced PET/CT also 
correctly diagnosed a benign lesion which presented 
as a suspicious adnexal mass causing moderate right 
hydronephrosis (Figure 3). 
Previously it has been reported that the sensitivity, 
specificity, positive predictive value and negative 
predictive value of PET/CT in detecting ovarian 
malignancy and metastases were 78%, 75%, 89% 
and 57% respectively  (10) and 87%, 100%, 81% and 
100% respectively.(11) Two recent studies also reported 
sensitivity and specificity of low dose PET/CT in detecting 
ovarian malignancy and metastases were 90% and 98% 
respectively(12) and 98.6% and 77.8% respectively.(13) 
Kitajima et al in 2008(14), stated that for the detection of 
ovarian cancer; the sensitivity, specificity and accuracy 
achieved integrated PET with CECT were 69.4%, 
97.5% and 94% respectively compared to their results 
in 2014(15) which were 82.6%, 100% and 86.7% 
respectively. A prospective study by Hynninen et al 
(2013) also stated that compared to CT alone, integrated 
contrast-enhanced PET/CT achieved better detection of 
carcinomatosis in the subdiaphragmatic peritoneum.
(16) These variations in percentage are likely due to do 
different resolutions of various PET/CT scanners as well 
as the utility of contrast media that helps improve lesion 
conspicuity.  
Modern PET/CT scanners have resolution of 4 – 5 mm 
due to developments in scintillation crystal detectors 
such as LSO that also operate in full 3D mode as well 
as utilize full system modelling iterative construction, 
that improve signal to noise ratio.(17) New generation 
scanners are also able to detect lesions as small as 0.5cm 
more accurately which can help improve radiation 
therapy planning.(18) This study achieved sensitivity, 
specificity, PPV and NPV of 91.7%, 100%, 100% and 
85.7% respectively for contrast-enhanced PET/CT. 
Conversely, CECT alone achieved sensitivity, specificity, 
PPV and NPV of   91.7%, 50.0%, 78.6%, and 75.0% 
respectively.
In our study, PET/CT also revealed improved detection 
of extra-abdominal metastasis, such as malignant 
pleural effusion (Figure 4a) and bone metastasis 
such as rib involvement (Figure 4b) as well as bowel 
involvement (Figure 4c); localization of distant nodal 
metastases at the abdominal para-aortic lymph nodes, 
as well as in the peritoneum and omentum. PET/
CT accurately detected distant extrapelvic nodal 
Fig. 4. Fused contrast-enhanced PET/CT images that demonstrate distant or occult metastases. (a): Axial view re-
vealed malignant pleural effusion (white arrow). (b): Left rib metastasis noted on coronal view images (white arrow). 
(c): Bowel metastasis at the terminal ileum and ascending colon noted in coronal view images (white arrow). (d): 
Upper abdominal/ subdiaphragmatic lymph node involvement (black arrow), as well as splenic metastases (white 
arrow), detected on axial view images. 
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involvement such as subdiaphragmatic lymph nodes 
(Figure 4d) ; giving sensitivity, specificity, PPV and 
NPV of 100%, 83.33%, 75.0% and 100% as compared 
to CT alone which gave results of 66.67%, 83.33%, 
66.67% and 83.33% respectively. In addition, PET/CT 
gave improved detection of peritoneal metastases with 
sensitivity, specificity, PPV and NPV of 100%, 50.0%, 
71.43% and 100% as compared to CT alone which gave 
80.0%, 75.0%, 80.0% and 75.0% respectively. Similar 
findings were noted in previous studies as elucidated by 
Yoshida et al, 2004.(7) Overall, contrast-enhanced PET/
CT was concordant with surgical staging in 7 out of 9 
women detected with ovarian malignancy, giving a 78% 
success rate. PET/CT upstaged one patient by detecting 
significantly elevated FDG uptake in the ribs and spine. 
Contrast-enhanced PET/CT altered the management 
in 36% of our cases. Furthermore, PET/CT affected 
stage migration and correctly upstaged 4 patients but 
wrongly down-staged one patient with borderline 
mucinous tumor. Traditionally, treatment for advanced 
disease involves using neoadjuvant chemotherapy i.e. 
standard platinum- and paclitaxel-based chemotherapy 
via intravenous and/or intraperitoneal route followed 
by optimal debulking surgery.(19) Patients at an early 
stage are likely to undergo primary cytoreduction 
surgery followed by chemotherapy as approximately 
80% of patients show good response to platinum-based 
chemotherapy.(20) 
In two of our patients with suspicious pelvic mass 
initially thought to be a primary ovarian cancer, PET/CT 
detected one case to be a primary ovarian carcinoma 
with bowel metastases (Fig. 4c) and the other was a 
colon cancer with secondaries to the ovaries. Both 
cases were initially planned for a primary cytoreductive 
surgery that included total abdominal hysterectomy and 
bilateral salpingo-oophorectomy (TAHBSO), but later 
had hemicolectomy added to their treatment. A case of 
a mucinous cystadenoma presented with a suspicious 
large pelvic mass as well as predominantly right-
sided hydronephrosis (Figure 3) and was planned for 
bilateral salpingo-oophorectomy, however it appeared 
benign on contrast-enhanced PET/CT and therefore, 
fertility conserving cystectomy was performed instead. 
Two cases had additional treatment regime proposed 
after reviewing PET/CT; a case of advanced mucinous 
Fig. 5. Proposed diagnostic imaging algorithm for management of ovarian cancer. [Information sourced from Mitch-
ell et al., 2013 and NICE Clinical Guidelines, 2011]
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carcinoma had NAC regime added on, to reduce the 
tumor burden detected on PET/CT and the other had 
radiotherapy proposed after PET/CT detected suspicious 
bony metastases which were not seen on CT alone 
(Figure 4b).
American College of Obstetrics and Gynecology 
(ACOG) guidelines on staging of ovarian cancer 
recommended that comprehensive surgical staging is 
necessary to detect occult metastatic disease and that 
computed tomography or magnetic resonance imaging 
(MRI) may be used to assess spread of disease and that 
PET/CT may play a role in detection of recurrence.(5) 
Thus, we propose a comprehensive diagnostic imaging 
algorithm for management of ovarian cancer (Figure 
5) which is based on NICE Guidelines, 2011(21) as 
well as from the American College of Radiology (ACR) 
appropriateness criteria for staging and follow-up of 
ovarian cancer.(22)”abstract” : “Imaging is used to 
detect and characterize adnexal masses and to stage 
ovarian cancer both before and after initial treatment, 
although the role for imaging in screening for ovarian 
cancer has not been established. CT and MRI have 
been used to determine the resectability of tumors, the 
candidacy of patients for effective cytoreductive surgery, 
the need for postoperative chemotherapy if debulking is 
suboptimal, and the need for referral to a gynecologic 
oncologist. Radiographic studies such as contrast 
enema and urography have been replaced by CT and 
other cross-sectional imaging for staging ovarian cancer. 
Contrast-enhanced CT is the procedure of choice for 
preoperative staging of ovarian cancer. MRI without and 
with contrast may be useful after equivocal CT, but is 
usually not the best initial procedure for ovarian cancer 
staging. Fluorine-18-2-fluoro-2-deoxy-D-glucose-PET/
CT may not be needed preoperatively, but its use is 
appropriate for detecting and defining post-treatment 
recurrence. Ultrasound is useful for evaluating adnexal 
disease, but has limited utility for staging ovarian 
cancer. The ACR Appropriateness Criteria are evidence-
based guidelines for specific clinical conditions that are 
reviewed every 2 years by a multidisciplinary expert 
panel. The guideline development and review include 
an extensive analysis of current medical literature from 
peer-reviewed journals and the application of a well-
established consensus methodology (modified Delphi 
The ACR proposes contrast-enhanced CT scan of the 
abdomen and pelvis as the investigation of choice for 
staging and follow-up of ovarian cancer, for MRI to be 
utilized in indeterminate cases, and considers 18F-FDG 
PET/CT as usually appropriate when investigating for 
recurrence. Currently, we do not propose for 18F-FDG 
PET/CT imaging to be utilized as a first line investigation 
tool because more research is needed to assess the cost 
benefit ratio of this test. Nevertheless, due to emerging 
knowledge regarding its clinical benefit, it can be 
proposed as an alternative imaging in indeterminate 
cases. 
The management of ovarian cancer in our local setting 
dictates the need for accurate pre-operative imaging. 
Generally, the treatment of choice for advanced ovarian 
cancer is neoadjuvant chemotherapy which is indicated 
when complete surgical debulking is impossible or when 
patient is unfit for surgery. In Malaysia, some patients 
with advanced stage resectable ovarian cancer are more 
likely to undergo primary debulking surgery followed 
by adjuvant chemotherapy. Although advanced ovarian 
cancer generally show some response to NAC and 
optimal debulking surgery, unfortunately, many of them 
develop recurrence and progressive metastatic disease, 
which leads to increased mortality.(19) Thus, contrast-
enhanced PET/CT has a role to play in correctly staging 
the disease pre-operatively to aid in optimal resection of 
malignant tissue. Contrast-enhanced 18F-FDG PET/CT 
is able to detect recurrence of ovarian cancer accurately 
in certain equivocal areas on low dose CT; such as in 
the retrovesical region, pelvic lymph nodes, abdominal 
lymph nodes,  supraclavicular lymph nodes, liver, and 
bones.(23)
We would like to suggest a one stop centre approach 
for contrast-enhanced PET/CT as most PET centres 
do not perform contrast-enhanced scans and only 
perform low dose CT scans for attenuation correction 
and anatomical localization. With the introduction of 
contrast-enhanced PET/CT, complete staging can be 
performed at one sitting thus reducing extra radiation 
to the patient. PET can highlight advanced disease 
better, thus making the clinician more confident about 
commencing neoadjuvant chemotherapy rather than 
attempting primary debulking surgery.
The limitation for this study was the small sample size 
as well as many of the cases were at an advanced 
stage thus potentially increasing the pre-test likelihood 
of detecting metastases. Future multi-centre studies in 
Malaysia may help to improve upon these limitations. 
Furthermore, a longer period of follow-up of these 
patients is recommended to assess the prognostic 
benefits of utilizing 18F-FDG PET/CT imaging in the 
management of suspicious adnexal masses.
As of yet, there is no standalone investigation that 
can yield excellent results for the diagnosis and 
management of ovarian cancers. Nevertheless, non-
invasive, improved diagnostic accuracy in the detection 
of ovarian cancer can be achieved using contrast-
enhanced 18F-FDG PET/CT imaging. Although it is not 
a mainstream investigation, it should be considered as 
an alternative investigation that can help in treatment 
planning and prognostication, especially in cases with 
equivocal findings by conventional imaging. 
PET/CT imaging in particular is gaining wider clinical 
acceptance due to the availability of hybrid scanners 
and to fulfil the need for functional imaging in the era 
of personalized medicine. In addition, there is a need 
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for further research to be done to evaluate the utility of 
Magnetic resonance / positron emission tomography 
(MR/PET) in the process of staging ovarian or fallopian 
tube cancers as it carries less risk of ionizing radiation 
compared to PET/CT. This can ultimately lead to 
improved prognosis and survival rates. 
CONCLUSIONS
Improved diagnostic accuracy for characterising 
benign and malignant adnexal masses can be achieved 
using contrast-enhanced 18F-FDG PET/CT, making 
it a potential investigation of choice which can help 
in treatment planning. We recommend the utility of 
our proposed diagnostic imaging algorithm because 
it will help in the management of adnexal masses by 
multidisciplinary teams in general, and radiologists and 
nuclear medicine physicians specifically.
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